Leerink Partnrs Comments on Edgewise Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:EWTX)

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for Edgewise Therapeutics in a research note issued on Thursday, August 8th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings of ($0.41) per share for the quarter. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.59) per share. Leerink Partnrs also issued estimates for Edgewise Therapeutics’ Q4 2025 earnings at ($0.55) EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02.

EWTX has been the topic of several other reports. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Edgewise Therapeutics in a research report on Wednesday, June 26th. Truist Financial restated a “buy” rating and set a $25.00 price objective on shares of Edgewise Therapeutics in a report on Wednesday, April 17th. Piper Sandler restated an “overweight” rating and issued a $48.00 target price on shares of Edgewise Therapeutics in a research note on Monday, July 1st. JPMorgan Chase & Co. increased their price target on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $32.00 price objective on shares of Edgewise Therapeutics in a research note on Thursday, July 25th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Edgewise Therapeutics presently has an average rating of “Buy” and a consensus target price of $33.40.

Edgewise Therapeutics Price Performance

Shares of EWTX stock opened at $17.05 on Monday. The stock’s 50-day moving average is $18.53 and its two-hundred day moving average is $17.87. Edgewise Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $23.50. The firm has a market cap of $1.59 billion, a P/E ratio of -11.00 and a beta of 0.14.

Institutional Investors Weigh In On Edgewise Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EWTX. Quest Partners LLC raised its position in shares of Edgewise Therapeutics by 156.9% during the second quarter. Quest Partners LLC now owns 1,742 shares of the company’s stock worth $31,000 after acquiring an additional 1,064 shares during the last quarter. Quantum Private Wealth LLC raised its stake in Edgewise Therapeutics by 2.4% during the 4th quarter. Quantum Private Wealth LLC now owns 63,219 shares of the company’s stock worth $692,000 after buying an additional 1,500 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Edgewise Therapeutics by 37.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,751 shares of the company’s stock valued at $105,000 after purchasing an additional 1,561 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Edgewise Therapeutics in the second quarter valued at approximately $35,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Edgewise Therapeutics by 29.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,833 shares of the company’s stock valued at $228,000 after acquiring an additional 4,785 shares in the last quarter.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.